To establish the prevalence of sexual dysfunction amongst HIV-positive men and to determine the factors associated with dysfunction we conducted a cross-sectional study in seven European HIV treatment centres. Data on medical history, antiretroviral treatment and laboratory results were collected by interview and case record review. Sexual function was evaluated by the participant self-completion of a questionnaire based on the International Index of Erectile Function (IIEF) 711/929. Seventy-seven percent of participants returned the questionnaire. Data from 668 (72%) respondents were included. Thirty-three percent (95%CI: 29.4 Á36.5%) had moderate/severe erectile dysfunction (EDF) and 24% (95%CI: 20.9 Á27.3%) had moderate to severe impairment of sexual desire. Variables significantly associated with EDF in multivariable analysis were older age (greater than 40 years), heterosexual status, non-alcohol drinking status, depression, antidepressants, psychotropic medications and duration of ARV therapy. Low sexual desire (LSD) was associated with older age (greater than 40 years), depression and black African ethnicity. We establish that EDF and LSD are common in both ARV naïve and ARV experienced, HIV-positive individuals. Erectile dysfunction was associated with long duration of ARV treatment, with a significantly increased risk of dysfunction in the quartile with the longest period of exposure. No significant association was seen with specific classes of anti-retrovirals. Older age, and depression were the variables most consistently associated with both EDF and LSD.
Introduction
Since the introduction of highly active antiretroviral therapy (HAART) there have been numerous reports of increased EDF in men. In these studies, prevalence rates of dysfunction of up to 70% have been described and in some the dysfunction has been linked with antiretroviral treatment (ARV), particularly protease inhibitors (PIs) Colson et al., 2002; Lallemand et al., 2002; Martinez et al., 1999; Schrooten et al., 2001; Sollima et al., 2001) .
However, proving a link between this unwanted outcome and ARV treatment is problematic. First, HIV infection may be associated with sexual dysfunction. There are several reports of sexual dysfunction that predate the introduction of HAART (Catalan et al., 1992a (Catalan et al., , 1992b and conditions commonly seen within the HIV context such as depression, peripheral neuropathy and hypogonadism are associated with sexual dysfunction in other settings. Secondly, establishing associations with particular drugs or classes of drugs is difficult, as these agents are used in combinations. Furthermore some of the ARV-associated toxicities, for example mitochondrial toxicities such as peripheral neuropathy can cause effects that persist. This could lead to the adverse effect being attributed wrongly to the treatments being taken at the time of assessment rather than to the treatment responsible.
In assessing the prevalence of sexual dysfunction in different groups, comparison of rates across different studies may also be misleading. Even when using the same assessment tool (IIEF) (Rosen et al., 1997) rates in different studies can vary markedly. For example the prevalence of moderate or severe EDF reported in a general Austrian population (Madersbacher et al., 2003) was as low as 5.8% while it was as high as 28% in a Singaporean study (Tan et al., 2003) . It is likely that such differences are caused by factors such as age, comorbidities and prescribed medications. In the studies in HIV-positive men, factors such as these have, in general, been poorly controlled for, hence we believe the confidence with which conclusions can be drawn from these studies is weakened.
The primary objectives of this study therefore are to establish the prevalence of EDF and LSD in both ARV naïve and experienced HIV-positive men attending HIV outpatient centres across Europe and to define the variables associated with sexual dysfunction. Due to the large number of variables that are potentially contributors to dysfunction, a large amount of data relating to these variables was collected. This not only included data relating to current HIV treatments but also previous treatments. Significant factors identified in univariate analysis were then examined further in a multivariable analysis.
Methods
Between April 2000 and May 2002 HIV-positive men attending one of seven European HIV treatment centres for routine HIV care were invited to join the study (the centres are those that were participants within the Eurosupport network and each centre obtained local ethics committee approval). If consent was given, two study components were administered. The study team completed the first part, which was a standardised data collection proforma that examined aspects of the medical history, antiretroviral treatment and laboratory results (total and fractionated cholesterol, triglycerides, testosterone, prolactin, lutenising hormone, follicle stimulating hormone and serum glucose). A large number of clinical data variables were examined in order to explore many possible associations.
The second part was a questionnaire (available in one of seven languages, English, French, German, Spanish, Italian, Dutch or Swedish) and was given to the participant to complete at home. This included questions assessing sexual function and other symptoms. Individuals were then asked to return this anonymous response by post to the coordinating centre. A code was used to link this to the data collected by the physician.
Sexual function was assessed within the questionnaire by questions based on the IIEF (Rosen et al., 1997) . We adapted the questionnaire given to homosexual men (MSM) by including questions assessing erectile and other sexual functions related to oro-genital and both insertive and receptive anogenital sex. This questionnaire was piloted amongst MSM prior to the study.
Categories of sexual function assessed were erectile function, sexual desire, orgasmic function, intercourse satisfaction and overall satisfaction. Based on these scores, each aspect of sexual function was categorised as normal or as mild, moderate or severe EDF. The analysis presented relates to the outcomes moderate to severe EDF and moderate to severe impairment of sexual desire. Univariate logistic regression analysis was used to identify risk factors associated with these outcomes. Variables found to be significant (p B/0.15) were used to build multivariable models in order to identify significant risk factors. Those variables co-correlated with other variables were left in the model to adjust for residual confounding. Due to the interaction between different ARV variables, different multivariable models were run examining the effect on the model of each of those ARV factors found to be significant in univariate analysis. The model presented includes ARV duration, as this was the strongest association seen. The multivariable model presents significant independent predictors after adjusting for other variables in the model. All p values presented are 2-tailed. To preserve degrees of freedom we examined CD4 counts categorised into groups using median and interquartile ranges with a separate category for missing data.
To examine links between sexual dysfunction and ARV combinations, individuals were categorised as either ARV naïve, ARV experienced but PI naïve, PI experienced and currently taking PI or PI experienced but not currently taking a drug from this class. Categories relating to the number of PIs, nucleoside reverse transcriptase inhibitors (NRTIs) and non-nucleoside reverse transcriptase inhibitors both currently and previously received were also examined. In order to negate the confounding of previous treatments on current treatment, a subanalysis of those on their first line ARV only was also performed.
As there was no consensus case definition for lipodystrophy at the time of study design, this was simply defined as having at one or more of the following symptoms confirmed by clinical examination: increase in abdominal girth, decrease of fat in the face and prominence of leg veins. Medications for psychiatric disorders assessed included antidepressants and other psychotropics (sedatives and major tranquillisers).
Results
Of the 929 individuals who consented for the study, 711 (77%) returned the questionnaire. Non-responders were more likely than responders to have an AIDS diagnosis (26.6% versus 20.5%; p0/ 0.005) and to ever have had diagnosed psychiatric disease (5% versus 1.8%; p0/0.033). Responders were more likely to be using methadone (5.9% versus 1.4%; p 0/0.005). There were no significant differences between responders and non-responders in reported co-morbidities or usage of sildenafil, testosterone, antidepressants or other psychotropic medication. Forty-four responses were excluded due to invalid or incomplete data. The overall response rate was 71.9%. In all, 486 of the participants were MSM and 182 heterosexual men, 552 were ARV experienced and 116 ARV naïve. Two hundred and twenty (32.9%; 95%CI: 29.4 Á36.5%) were categorised as having moderate/severe EDF and 161 (24.1%; 95%CI: 20.9 Á27.3%) moderate/severe LSD.
Erectile dysfunction
Overall, 35% of ARV experienced participants reported moderate or severe EDF compared with 22% of those who were ARV naïve. The factors associated with EDF in univariate analysis are shown in Table I . When a multivariable model was run with treatment experienced versus naïve as the ARV associated variable this association was not found to be significant (OR ARV naïve 0.69; 0.39 Á1.22; p 0/0.201). However, examining duration of ARV use we found that the most experienced group (greater than 81 months on treatment) were significantly more likely than the other groups of ARV experienced and naïve participants to report EDF ( Figure 1 ). We also performed models to examine whether there was an association between EDF and duration of exposure to either NRTIs or to PIs. In neither of these multivariable analyses was a significant association seen.
Low sexual desire
Overall 26% of ARV participants reported moderate to severe reduction in sexual desire compared with 13% of those who were ARV naïve. While this difference was significant in univariate analysis this was not the case when we used this as the ARV variable in multivariable analysis (OR ARV naïve 0.63; 0.32 Á1.21; p0/0.166). We did not demonstrate an association between LSD and any ARV related variable (see Figure 2 ).
When we analysed those individuals on their first line therapy only (n 0/ 86) the variables significantly associated with EDF were older age, heterosexual status, smoking status, reported fatigue, pain in bones and joints and pins and needles in hands and feet. Being on a protease inhibitor containing combination was not associated with EDF.
As a supplement to the study we asked participants reporting EDF whether they had used therapies to treat this condition. The most frequent reported therapy was sildenafil, used by 112 individuals (16%). Smaller numbers reported using testosterone, growth hormone, yohimbine, alprostadil and papaverine. Twenty-six individuals reported they had changed their ARV combination and 26 reported they had stopped their ARV drugs in an attempt to improve sexual function. Within these two groups twenty-two individuals (42%) reported either manoeuvre to have been successful.
Discussion
While in univariate analysis ARV-experienced participants were significantly more likely than ARVnaïve individuals to experience EDF, when the data were adjusted in multivariable analysis we were unable to demonstrate a significantly higher prevalence of dysfunction in this group. In running several models, the only treatment-related variable associated with a significantly increased prevalence of dysfunction was in the quartile of patients with the longest duration of ARV treatment (greater than 81 months) where the relative risk of moderate/severe EDF was approximately three times that seen in ARV naïve individuals. Increased rates of dysfunction were not seen in individuals with less exposure to ARVs compared to treatment naïve individuals.
Most studies of EDF in people with HIV infection done since the introduction of HAART have looked only at individuals taking ARV treatment and so direct comparison with ARV naïve groups has not been possible. In the one study that did look at both groups, sexual dysfunction was seen in many more of the ARV treated individuals. However in this study the method of assessment was not well described nor were factors such as age controlled for.
We found no assciation between EDF and either categorical exposure or duration of exposure to specific classes of NRTI or PI therapy. While several studies have demonstrated an association with PIs Colson et al., 2002; Martinez et al., 1999; Schrooten et al., 2001) it is interesting that neither of the two groups that utilised the IIEF found a link with a particular class of medications (Lallemand et al., 2002; Sollima et al., 2001) .
That EDF was associated with duration of ARV exposure, allied with the fact that both NRTIs and PIs are associated with toxicities that might be related to cumulative exposure (for example metabolic and mitochondrial toxicities) raises the possibility that sexual dysfunction may in some way be related to these toxicities. For example EDF has been seen in association with peripheral neuropathy and is also hypothesised to be associated with endothelial dysfunction seen in forms of metabolic syndrome (Esposito et al., 2005; Fonseca & Jawa, 2005) . We were not, however, able to demonstrate a link with clinical manifestations of such toxicities except for the single association of reported tingling in the extremities (indicative of peripheral neuropathy) and LSD. Lallemand et al. (2002) also Sexual dysfunction amongst HIV-positive men Sexual dysfunction amongst HIV-positive men 961 reported the absence of an association between EDF and lipodystrophy.
Older age was the variable most strongly associated with both EDF and LSD aspects of decreased sexual function. The risk of moderate to severe EDF for an individual in the oldest quartile was almost three times that for someone in the youngest quartile. Studies of EDF in the general population consistently demonstrate older age as one of the variables most strongly associated with dysfunction.
There was an association between anti-depressants and other psychotropic medication and EDF. Although anti-depressants, psychotropic medica-tions, anti-hypertensives and statins have all been previously linked to sexual dysfunction (Bruckert et al., 1996; Rizvi et al., 2002) it remains problematic proving causality particularly when underlying conditions such as depression may be exerting an influence (Araujo et al., 1998) . In the Massachusettts male aging study, the apparent associations between medications and sexual dysfunction mostly disappeared when adjustment for co-morbidities and health behaviours was made (Derby et al., 2001) . While we enquired broadly about relationship problems we did not explore some other issues that might have had influence. Previously factors such as discordant HIV status, disclosure status and the type and nature of sexual relationships have been postulated to affect sexual function.
Most participants who switched or stopped ARV medications due to EDF came off PI based regimens. While a percentage of these individuals reported improvement, it is not necessarily correct to conclude from this that the ARV agents were responsible for the dysfunction.
The prevalence of moderate/severe LSD was lower than that of EDF. No ARV associated variable that we tested was associated with LSD in multivariable analysis.
There are limitations to the study. The participation of centres and subjects from different countries presented many challenges. While guided by study protocols and proformas, there may have been differences in the way in which individuals were recruited and how data was collected. Although the study recruitment protocol was inclusive and nonselective it is possible that there was a bias in patient selection and that therefore the study group is not representative of the entire clinic population. While the MSM adapted questionnaire was piloted it was not formally validated. It is possible that some of the increased risk of sexual dysfunction seen in heterosexual men relates to assessment of dysfunction rather than any inherent difference. Lastly, the large number of variables examined increases the possibility of finding a spurious association by chance and also the possibility that a positive association was lost by the dilutional effect of including so many variables.
We have demonstrated a high prevalence of sexual dysfunction in both ARV treatment naïve and experienced individuals. Sexual dysfunction is associated with older age, depression and longer duration of ARV. We were not able to demonstrate an association between EDF and a particular class of ARV or with specific HIV or drug-related toxicities. That sexual dysfunction is multi-factorial is an important finding. For those affected it is often a major concern and leads to considerable diminution in quality of life. There is also evidence that the attribution of sexual dysfunction to PI is contributing to lower levels of adherence over time (Trotta et al., 2003) . In these circumstances it remains important to discuss with patients the uncertainty over this association and to assess, investigate and treat this condition appropriately. Meanwhile further, preferably prospective, study is required so that any relationship with ARV or related conditions can be further defined.
